Compare Cibus, Inc. (CBUS) vs BiomX Inc. (PHGE) Stock

Analysts rate Cibus, Inc. (CBUS) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cibus, Inc. (CBUS) delivered a total return of -99.1%, compared to -99.5% for BiomX Inc. (PHGE). A $10,000 investment in CBUS five years ago would be worth approximately $91 today (assuming dividends reinvested). Over 10 years, the gap is even starker: CBUS returned -99.4% versus PHGE's -99.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BiomX Inc. (PHGE) is the lower-risk stock at 0.93β versus Cibus, Inc.'s 1.89β — meaning CBUS is approximately 104% more volatile than PHGE relative to the S&P 500. On balance sheet safety, Cibus, Inc. (CBUS) carries a lower debt/equity ratio of 37% versus 40% for BiomX Inc. — giving it more financial flexibility in a downturn.

BiomX Inc. (PHGE) is the more profitable company, earning 0.0% net margin versus -59.0% for Cibus, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0.0% versus -60.6% for CBUS. At the gross margin level — before operating expenses — CBUS leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BiomX Inc. (PHGE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.93)). Cibus, Inc. (CBUS) carries a higher beta of 1.89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PHGE: -99.7%, CBUS: -99.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.